Another 36million can now access Penthrox for pain relief. $3...

Another 36million can now access Penthrox for pain relief.

$3 million milestone payments can be achieved. See Purdue announcement from 12 Sept 2016:


MVP Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox® in Canada
(Pickering, Canada and Victoria, Australia, 12 September 2016) Medical Developments International Limited (“MDI”) (ASX: MVP) is delighted to announce it has reached an exclusive distribution and licensing agreement with Purdue Pharma (Canada) for Penthrox® (Low-Dose Methoxyflurane) Inhaler in Canada.
Penthrox® is a fast-acting, inhaled, non-narcotic analgesic drug / device combination for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain. Penthrox is approved for marketing in 15 countries (including: Australia, UK, Ireland, France and Belgium). It has been marketed in Australia since 1975.
The CEO of MDI, Mr. John Sharman said: “This is an exciting deal for MDI and is a critical step towards providing the Canadian healthcare system with another valuable therapeutic option for the treatment of pain. Purdue has market leading expertise in pain management products and will invest in providing the educational resources to healthcare practitioners on the appropriate use, benefits, and safety profile of Penthrox.”
Dr. Craig Landau, President and CEO, Purdue Pharma (Canada) added: “Subject to regulatory approval by Health Canada, Penthrox will provide Canadian patients and ER Physicians with an important, non-opioid treatment option for medical situations involving acute trauma pain that is moderate to severe in nature. Penthrox nicely complements, and will provide additional diversification to our existing analgesic product portfolio. We look forward to making Penthrox available to health care professionals and the patients who would benefit from its use in appropriate settings.”
Purdue Canada will pay MDI up to $3M CAD through a combination of upfront, milestone, and success based payments.
For more information and media inquiries, please contact:
Medical Developments International